Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

SALT LAKE CITY — "More men die with prostate cancer than because of it" has become a common phrase used when discussing prostate cancer. While it can be true for some men, the reality is that regular ...